Over the past year there were no insider purchases at Pliant Therapeutics, Inc.. Four insiders sold roughly $164,000 instead.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Big money check: 86 institutions held PLRX as of Q2 2026, and more funds sold than bought. No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | Cummings Keith Lamont | CFO | Sell | 24,002 | $1.28 | $31K | SEC |
| Jan 22, 2026 | Cheung Lily | Executive Officer | Sell | 7,534 | $1.28 | $10K | SEC |
| Jan 22, 2026 | Coulie Bernard | CEO | Sell | 89,375 | $1.28 | $114K | SEC |
| Jan 22, 2026 | Kuo Minnie | COO | Sell | 6,917 | $1.28 | $9K | SEC |
| Jan 22, 2025 | Coulie Bernard | CEO | Sell | 52,419 | $11.20 | $587K | SEC |
| Jan 22, 2025 | Cummings Keith Lamont | CFO | Sell | 20,148 | $11.20 | $226K | SEC |
| Jan 22, 2025 | Hull Hans | Executive Officer | Sell | 15,936 | $11.20 | $178K | SEC |
| Jan 22, 2025 | Lefebvre Eric | Executive Officer | Sell | 18,478 | $11.20 | $207K | SEC |
| Jan 22, 2025 | Cheung Lily | Executive Officer | Sell | 3,740 | $11.20 | $42K | SEC |
| Jan 22, 2025 | Ouimette Mike | Executive Officer | Sell | 13,270 | $11.20 | $149K | SEC |
| Jan 22, 2025 | Ouimette Mike | Executive Officer | Sell | 10,230 | $10.99 | $112K | SEC |
| Jul 12, 2024 | Lefebvre Eric | Executive Officer | Sell | 12,319 | $11.56 | $142K | SEC |
| Jul 12, 2024 | Hull Hans | Executive Officer | Sell | 9,900 | $11.56 | $114K | SEC |
| Jul 12, 2024 | Cummings Keith Lamont | CFO | Sell | 10,911 | $11.56 | $126K | SEC |
| Jul 12, 2024 | Ouimette Mike | Executive Officer | Sell | 7,656 | $11.56 | $89K | SEC |
In the last 12 months Pliant Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $164,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in PLRX was filed on 2026-01-22.
86 investment managers reported holding PLRX in SEC Form 13F filings for Q2 2026.
No congressional trades in PLRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).